
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp has demonstrated significant growth in its glaucoma revenue, achieving $110 million in the third quarter of 2025, surpassing consensus estimates and reflecting a 45% increase year-over-year, with notable domestic sales up 57%. The company's operating margin improved to (7.0%), showing a substantial year-over-year increase of 1,210 basis points and exceeding market expectations. Additionally, Glaukos's Corneal Health segment has experienced a robust compound annual growth rate (CAGR) of approximately 15.2% globally since 2020, with positive adoption trends for its Epioxa therapy indicating increased future utilization among potential adopters.
Bears say
Glaukos Corp faces significant headwinds that contribute to a negative outlook on its stock, primarily due to projected slower growth in the micro-invasive glaucoma surgery (MIGS) market and challenges in the adoption of its iDose TR and iStent infinite products. Sales data indicates a concerning decline in legacy surgical glaucoma products, with a reported 4.7% decrease, along with expectations of a material decline in corneal health revenues as it transitions to the Epioxa product. Additionally, potential alterations in the reimbursement landscape and slower-than-anticipated product launches further intensify the risks associated with Glaukos's future financial performance.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares